Minerva urology and nephrology · 2025
Teupolioside and Graminex (Xipag®) combined therapy induced anti-inflammatory effects and decreased dihydrotestosterone levels in the prostate tissue of patients with benign prostate hyperplasia: results of a pilot study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bartoletti Riccardo, Faviana Pinuccia, Giannini Riccardo, Bartoli Francesco, Dazzi Filippo, Antonov Petar, Ivanov Atanas, D'Argliano Virginia, Volterrani Rachele, Pacini Matteo, Zucchi Alessandro
Аннотация
BACKGROUND: Teupolioside effectively reduced hirsutism in policystic ovary sindrome by lowering hormonal levels, thus suggesting potential for benign prostatic hyperplasia (BPH) treatment. This study will assess Dihydrotestosterone (DHT) levels and prostate inflammation in BPH patients before and after Xipag® (Ajuga Reptans extract) administration.
METHODS: Formalin-fixed paraffin embedded (FFPE) samples from prostate biopsies (PB) and trans-urethral resection (TURP) specimens of 10 patients with elevated Prostate Specific Antigen (PSA) were analyzed. All had prostate inflammation and BPH at biopsy and received Xipag® (1 tablet/day, median 50 days) between PB and TURP. DHT tissue levels, CD4+, and CD8+ lymphocyte expression were assessed via 3'-3' diaminobenzidine staining on 5 µm sections. Serum PSA levels were measured before PB and prior to TURP. All antigens were visualized using the same secondary antibody, producing a uniform brown stain. A paired t-test compared conditions.
RESULTS: Total PSA serum levels dropped from 4.21 (3.61-8) ng/mL pre-PB to 2 (1.53-3.03) ng/mL post-Xipag® and pre-TURP (P=0.016). Xipag® significantly reduced CD4+ recruitment by 46.1% and increased CD8+ by 19.89%, enhancing CD4+ target cell elimination (P=0.0003; P=0.0006), indicating inflammatory normalization in BPH tissue. DHT expression decreased by 26.67% post-treatment (P=0.0002; CI -36.08, -17.25).
CONCLUSIONS: The short period of Xipag® administration effectively reduced DHT and PSA levels in patients affected by BPH. Additionally, it decreased CD4+ T lymphocyte infiltration while promoting CD8+ T lymphocytes, leading to a normalization of the prostate tissue inflammatory infiltrate.
METHODS: Formalin-fixed paraffin embedded (FFPE) samples from prostate biopsies (PB) and trans-urethral resection (TURP) specimens of 10 patients with elevated Prostate Specific Antigen (PSA) were analyzed. All had prostate inflammation and BPH at biopsy and received Xipag® (1 tablet/day, median 50 days) between PB and TURP. DHT tissue levels, CD4+, and CD8+ lymphocyte expression were assessed via 3'-3' diaminobenzidine staining on 5 µm sections. Serum PSA levels were measured before PB and prior to TURP. All antigens were visualized using the same secondary antibody, producing a uniform brown stain. A paired t-test compared conditions.
RESULTS: Total PSA serum levels dropped from 4.21 (3.61-8) ng/mL pre-PB to 2 (1.53-3.03) ng/mL post-Xipag® and pre-TURP (P=0.016). Xipag® significantly reduced CD4+ recruitment by 46.1% and increased CD8+ by 19.89%, enhancing CD4+ target cell elimination (P=0.0003; P=0.0006), indicating inflammatory normalization in BPH tissue. DHT expression decreased by 26.67% post-treatment (P=0.0002; CI -36.08, -17.25).
CONCLUSIONS: The short period of Xipag® administration effectively reduced DHT and PSA levels in patients affected by BPH. Additionally, it decreased CD4+ T lymphocyte infiltration while promoting CD8+ T lymphocytes, leading to a normalization of the prostate tissue inflammatory infiltrate.